23.09.2025
Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation
22.09.2025
Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
16.09.2025
Akeso’s Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
Who We Are?
A pioneer in developing innovative antibodies

Akeso, Inc. (HKEX Code: 9926. HK) is a biopharmaceutical company founded by a team of scientists with rich experience in global drug development and focuses on the unmet clinical needs worldwide in major diseases. The Company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) ,ADC technology ,mRNA technology and  the cell therapy technology as the core, a GMP-compliant manufacturing system, and a commercialization system with an advanced operation mode. 

Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values so as to become a leading global biopharmaceutical enterprise.

Collaborations
Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

Summit白字logo 50Px高 logo图层 0 (4) logo辉瑞裁剪版白字 50Px高 logo图层 3 (1) logo图层 4 (1) logo图层 1 (1) logo图层 2 (1) logo
Pipelines
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

Asd654f56q56er4en logo